However, men with higher PSA levels did show modest improvements in survival, suggesting that hormone therapy might be worthwhile for them. PSA (prostate-specific antigen) is produced by the prostate ...

A meta-analysis explores whether there’s a survival benefit to adding hormone therapy to postoperative radiation for patients with low PSA levels.

Adding hormone therapy to postoperative radiotherapy did not improve OS for most patients ...

Prostate cancer is the most common cancer in men throughout the United States. Most men do not realize they have cancer due ...

No significant improvement seen in overall survival with addition of hormone therapy to post-radical prostatectomy radiotherapy.

MARCAP investigators conducted the first individual patient data meta-analysis of randomized trials (POSEIDON) evaluating the use and duration hormone therapy with postoperative radiation therapy in ...

Oxybutynin significantly reduced hot flash frequency and severity compared with placebo among men with prostate cancer ...

Historically, treatment for metastatic prostate cancer relied heavily on androgen deprivation therapy (ADT) alone. Over time, research has demonstrated that combining ADT with additional agents ...

Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with ...

Men with aggressive prostate cancer, often left with few options after chemotherapy fails, now have access to a new treatment that uses a radioactive substance.The new treatment, Lutetium-177 PSMA ...

Niraparib and abiraterone acetate regimen demonstrates clinically meaningful delay in disease progression, nearly halving the risk of progression or death, with an early trend toward improved overall ...